Korea Kolmar to develop topical agent for treatment of osteoporosis

Published: 2008-07-18 06:42:00

Updated: 2008-07-18 06:42:00

Korea Kolmar is aiming to develop a new topical drug containing calcitonin and bisphosphonates to treat osteoporosis by spending 3.5 billion won for the next three years, under the joint collaboration with the Korea Research Institute of Chemical Technology and Sookmyung Women’s University’s phar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK